Alumis (ALMS) Total Non-Current Liabilities (2023 - 2025)
Alumis (ALMS) reported Total Non-Current Liabilities of $110.5 million for Q4 2025, up 38.02% year-over-year from $80.1 million in Q4 2024, and up 7.23% quarter-over-quarter from $103.1 million in Q3 2025.
Alumis (ALMS) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Total Non-Current Liabilities data on file, last reported at $110.5 million in Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $110.5 million, up 38.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $110.5 million (up 38.02% YoY), and the FY2025 annual result was $110.5 million, up 38.02% from the prior year.
- Total Non-Current Liabilities advanced to $110.5 million in Q4 2025 per ALMS's latest filing, from $103.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $125.2 million in Q2 2025 and troughed at $51.7 million in Q4 2023.
- A 3-year average of $86.2 million and a median of $86.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 97.3% in 2025 and fell as far as 38.02% in 2025.
- A 3-year view of Total Non-Current Liabilities shows it stood at $51.7 million in 2023, then surged by 54.79% to $80.1 million in 2024, then soared by 38.02% to $110.5 million in 2025.
- Business Quant data shows ALMS's Total Non-Current Liabilities at $110.5 million in Q4 2025, $103.1 million in Q3 2025, and $125.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | 110.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.52 Mn |
| Sep 30, 2025 | 103.07 Mn |
| Jun 30, 2025 | 125.21 Mn |
| Mar 31, 2025 | 92.40 Mn |
| Dec 31, 2024 | 80.08 Mn |
| Sep 30, 2024 | 63.15 Mn |
| Jun 30, 2024 | 63.46 Mn |
| Dec 31, 2023 | 51.73 Mn |